CGEN-15029 is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen. It has been validated as an immune-suppressive protein that is able to inhibit activation of T cells by tumor cells. A lead therapeutic antibody has been selected, and is currently undergoing preclinical development.
CGEN-15029 is also being assessed for anti-cancer activity through a different mechanism of action, by engaging effector cells of the immune system to directly kill tumor cells, and in particular T cell leukemias. This mechanism of action is supported by preliminary pre-clinical activity using a different CGEN-antibody against CGEN-15029. We are assessing the medical need and business opportunity.